MIM
GENB

MetLife Investment Management’s Generate Biomedicines GENB Stock Holding History

MetLife Investment Management’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$250K Buy
+14,841
New +$202K ﹤0.01% 2304

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

MetLife Investment Management's GENB Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Generate Biomedicines (GENB) in Q2 2026: 14,841 shares worth $250K. The stake represents ﹤0.01% of the portfolio and ranks #2304 among its holdings.

86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • MetLife Investment Management held 14,841 shares of Generate Biomedicines worth $250K as of Q2 2026.
  • Generate Biomedicines was a new MetLife Investment Management position in Q2 2026.
  • Generate Biomedicines made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2304 holding.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.